Sernova

Sernova Corp.

Stock Exchange Listing
TSX(v): SVA.V


Tel: 1 (877) 299-4603
Tel: (519) 858-5184
Fax: (519) 858-5099
info@sernova.com



Business Development

Philip Toleikis
Tel: (604) 961-2939
info@sernova.com



Investor Relations

Ray Matthews
Ray Matthews & Associates, Inc.
Tel: (604) 818-7778
ray@raymatthews.ca



Address

Sernova Corp.
700 Collip Circle, Ste 114
London, ON
Canada N6G 4X8

    Cell Pouch System™

    Cell Pouch System™

    Sernova’s Cell Pouch System™ is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells. These therapeutic cells release necessary proteins or hormones missing from the body to treat chronic diseases as an alternative to daily administration of drugs.

    Read More…
    Sertolin™

    Sertolin™

    Sertolin™ provides an immune-protected local environment for transplanted therapeutic cells such as insulin producing islets by producing factors which modulate the local immune response. Sertolin™ may reduce or eliminate the need for immunosuppressant agents.

    Read More…
    Go Back

    Dr. David White (Chair)

    Chairman - Scientific Advisory Board


    Dr. White graduated from the Universities of Surrey and Cambridge and in 1975 was awarded a PhD in Immunology from Cambridge.

    He was Board Certified in Pathology in 1984 (MRCPath) and elected as a fellow of the college in 1995 (FRCPath). Dr. White holds appointments on the Editorial Board of several major international transplantation journals, has served as a member of government advisory committees, and has been awarded a number of academic prizes for his work.

    He has published over 300 scientific papers on subjects related to transplant immunology.

    Dr. White first became interested in transplantation while undertaking research at the Department of Surgery at Cambridge University in the 1970s.

    In conjunction with Professor Sir Roy Calne, he undertook much of the original experimental and clinical work that led to the development of the immunosuppressive drug Cyclosporin A.

    The drug became pivotal in preventing organ rejection following transplantation and has allowed new transplantation procedures to be developed.

    His research into the immunological process underlying rejection of organ transplants led him to investigate how the immune system could be modified to enable successful transplantation of non-human organs - potentially solving the 'organ donor crisis'.

    These studies led Dr White in 1992 to create the world's first genetically engineered pigs whose organs and tissues were modified for transplantation into humans.

    In 1984 he and transplant surgeon John Wallwork founded Imutran Limited, which became a wholly owned subsidiary of Novartis Pharma AG in 1996, and Dr White was appointed to the Novartis Global Research Management Board.

    In 2000 Dr White was appointed the Novartis/Stiller Professor of Xenotransplantation at the University of Western Ontario.

    Go back

      Company History

      Sernova was founded in 2006 - London, Ontario;


      2006

      On September 20, the Company announced it had received TSX Venture Exchange approval to change its name to Sernova Corp.


      2005

      In April the Board of Directors brought in a new management team to find viable research and development projects suitable for the Company. On May 16, 2006 the Company announced it had closed a joint venture agreement with Sertonex Inc., a private medical research company based in London Ontario, and Sertoli Technology Inc., a private intellectual property company based in Tucson Arizona. The joint venture allows the Company to own the exclusive rights to the research efforts and intellectual property related to a potential breakthrough treatment for diabetes. That project is now the Company's main focus.


      2004

      On May 4th, Pheromone Sciences Corp announced the conclusion of negotiations with HealthWatchSystems, Inc. of Sarasota, Florida for the sale of all patents, intellectual property and supplies related to the Fertility Monitor. At the company's annual and special shareholder meeting on August 25, 2004, the sale was accepted by the shareholders and the asset sale agreement was then closed on August 31, 2004. The monitor is now sold under the name OV-Watch and Sernova receives royalties on the net sales.


      2000

      In February, through a Share Exchange Agreement, PCS was acquired by Mecca Medi-Tech Inc. (MEC), a venture capital pool company trading on the Canadian Venture Exchange. The combined new entity was named Pheromone Sciences Corporation.

      Pheromone Sciences first commercial product brought to market was the PSC Fertility Monitor. The monitor set a new benchmark in family planning and provides a more reliable and user-friendly approach to natural, cycle-based fertility status measurement. The PSC Fertility Monitor is a non-invasive method of predicting ovulation and the fertile window of women through the measurements of sweat ion changes on the surface of the skin. It is a small wristwatch-like device, containing an interactive microprocessor combined with a biochemical sensor allowing it to produce data that predicts the fertility status of the user (not-fertile, fertile or ovulating). The computed results can then be viewed on the LCD screen of the device and/or the user can be alerted via optional audio signals.


      1997

      PCS succeeded in characterizing a human (female) pheromone, naming it PSC Synchronin.


      1992

      Pheromone Sciences Corporation (PCS) was a private corporation founded by Doug Marett, M.Sc. in 1992.